Trials / Unknown
UnknownNCT02430974
Chemotherapy of NSCLC With or Without Icotinib
Icotinib as Maintenance Treatment After Chemotherapy for Patients Undergoing Resection of EGRF Mutation-positive Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients with EGFR-tyrosine kinase inhibitors (EGFR-TKI) confers a significant survival benefit. This study assessed the efficacy and safety of chemotherapy with or without icotinib in patients undergoing resection of stage IB to IIIA EGFR-mutated NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icotinib | Patients in experimental group will receive oral Icotinib for 4-8months. |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2016-01-01
- Completion
- 2018-01-01
- First posted
- 2015-04-30
- Last updated
- 2015-04-30
Source: ClinicalTrials.gov record NCT02430974. Inclusion in this directory is not an endorsement.